SPSanjay Pujari

Sanjay Pujari

*This is an algorithmically generated author record based on publicly available information.

Sanjay Pujari has a total of 171 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Validity of Blood Urea Nitrogen to Serum Albumin Ratio as an Independent Biomarker to Predict Severity and Mortality of Community-acquired Pneumonia

    by Vihita Kulkarni, Arun Bahulikar, Deepak Phalgune, Sanjay Pujari, Abdeali Ginwala

    Certain serum biomarkers have been reported to predict the severity and mortality of community-acquired pneumonia (CAP). There is a dearth of studies on this subject in the Indian population in patients with CAP. The present prospective observational study was conducted to find the utility of the blood urea nitrogen (BUN)/serum albumin (B/A) ratio as a biomarker to predict the severity and mortality in patients with CAP. All 90 patients aged ≥ 18 years of either sex, with a new radiographic infiltrate, were included. Various biochemical parameters such as BUN, serum albumin, and procalcitonin were tested. The serum B/A ratio was calculated. A chest radiograph was obtained. Patients were followed up for the duration of their stay in hospital till discharge or death. The sensitivity and specificity of the B/A ratio at the optimum cut-off value of 10.66 to predict the severity of CAP was about 79.0%, whereas the sensitivity and specificity of the procalcitonin at the optimum cut-off value of 1.50 ng/dL to predict the severity of CAP were 71.15 and 84.21%, respectively. The sensitivity and specificity of the B/A ratio at the optimum cut-off value of 19.8 to predict the mortality of CAP was about 99.0%, whereas the sensitivity and specificity of the procalcitonin at the optimum cut-off value of 5.55 ng/dL to predict the mortality of CAP was about 92.0%. The B/A ratio and procalcitonin are simple but independent predictors of mortality and severity of CAP. Ginwala A, Pujari S, Phalgune D, Kulkarni V, Bahulikar A. Validity of Blood Urea Nitrogen to Serum Albumin Ratio as an Independent Biomarker to Predict Severity and Mortality of Community-acquired Pneumonia. Indian J Crit Care Med 2025;29(4):333–337.


  • Effectiveness, Weight Changes, and Metabolic Outcomes on Switch to Generic Dolutegravir/Lamivudine Among People with HIV in Western India: An Observational Study

    by Sanjay Pujari, Sunil Gaikwad, Suhrud Panchawagh, Abhishek Chitalikar, Kedar Joshi, Chaitrangi Rohekar, Diagamber Dabhade, Vivek Bele

    We assessed the effectiveness and safety of switching to generic dolutegravir/lamivudine (DTG/3TC) among People living with Human Immunodeficiency Virus (PWH) in Western India. In this single-center, retrospective observational study, PWH, who switched to DTG/3TC, were followed for virologic, immunologic, and clinical effectiveness, and safety, including weight changes, hyperglycemia, and dyslipidemia. Multivariate linear mixed-effects models were used to predict average change in weight adjusted for age, sex, duration of previous antiretroviral (ARV) regimens, and baseline weight. From May 2017 to July 2022, out of 434 PWH switched to DTG/3TC, 304 with at least 1 follow-up visit were included. Median [interquartile range (IQR)] age was 54 (IQR 49–61) years and 70.1% were male. Prevalence of baseline comorbidities was 57.9% (hypertension—41.5%, chronic kidney disease—40.9%, and diabetes mellitus—18.8%). Reasons for switch were affordability (47.4%), desire for simplification (41.8%), ARV toxicities (19.1%), and concern about potential toxicities (10.2%). Median (IQR) duration of follow-up on DTG/3TC was 40 (IQR 31–49) weeks. No virologic failure was observed. Rates of virologic suppression [viral load (VL) ≤20 copies/mL or target not detected (TND)] at 12, 24, 48, 72, 96 and 120 weeks were 95.2%, 95.9%, 90%, 100%, 81.3%, and 88.4%, respectively. Only 9 (3%) PWH permanently discontinued DTG/3TC. Predicted adjusted mean weight gain of +3.3 kg was observed at 96 weeks. Switching from tenofovir disoproxil fumarate (TDF)/emtricitabine or lamivudine (XTC)/non-nucleoside reverse transcriptase inhibitor (NNRTI) and duration on DTG/3TC were significantly associated with weight gain. Apart from trend in worsening hyperglycemia (nine PWH with new onset diabetes), no clinically significant change in lipids and estimated glomerular filtration rate (eGFR) was documented. Switching to DTG/3TC is an effective and safe option among virologically suppressed PWH with high comorbidity burden in India. In view of the several advantages of DTG/3TC, it may be considered for potential scale-up in the right population, both in private and public health care settings in India.


  • Open Access

    Virological failure and treatment switch after ART initiation among people living with HIV with and without routine viral load monitoring in Asia

    by Sirinya Teeraananchai, Matthew Law, David Boettiger, Nicole De La Mata, Nikhil Gupte, Yun‐Ting Lawrence Chan, Thach Ngoc Pham, Romanee Chaiwarith, Penh Sun Ly, Sasisopin Kiertiburanakul, et al.

    Introduction: Viral load (VL) testing is still challenging to monitor treatment responses of antiretroviral therapy (ART) for HIV treatment programme in Asia. We assessed the association between routine VL testing and virological failure (VF) and determine factors associated with switching to second‐line regimen.Methods: Among 21 sites from the TREAT Asia HIV Observational Database (TAHOD), people living with HIV (PLHIV) aged ≥18 years initiating ART from 2003 to 2021 were included. We calculated the average number of VL tests per patient per year between the date of ART initiation and the most recent visit. If the median average number of VL tests was ≥ 0.80 per patient per year, the site was classified as a routine VL site. A site with a median < 0.80 was classified into the non‐routine VL sites. VF was defined as VL ≥1000 copies/ml during first‐line therapy. Factors associated with VF were analysed using generalized estimating equations with Poisson distribution.Results: Of 6277 PLHIV starting ART after 2003, 3030 (48%) were from 11 routine VL testing sites and 3247 (52%) were from 10 non‐routine VL testing sites. The median follow‐up was 9 years (IQR 5–13). The median age was 35 (30–42) years; 68% were male and 5729 (91%) started non‐nucleoside reverse‐transcriptase inhibitor‐based regimen. The median pre‐ART CD4 count in PLHIV from routine VL sites was lower compared to non‐routine VL sites (144 vs. 156 cells/mm3, p 3. A total of 817 (13%) patients switched to second‐line regimen at a rate of 1.44 (95% CI 1.35–1.54) per 100 PY. PLHIV at routine VL monitoring sites were at higher risk of switching than those at non‐routine VL sites (adjusted sub‐hazard ratio 1.78 95% CI [1.17–2.71]).Conclusions: PLHIV from non‐routine VL sites had a higher incidence of persistent VF and a low switching regimen rate, reflecting possible under‐utilized VL testing.


  • BMI as a predictor of high fasting blood glucose among people living with HIV in the Asia‐Pacific region

    by Dyna Khuon, Dhanushi Rupasinghe, Vonthanak Saphonn, Tsz‐Shan Kwong, Alvina Widhani, Romanee Chaiwarith, Penh Sun Ly, Cuong Duy Do, Anchalee Avihingsanon, Suwimon Khusuwan, et al.

    Background: Non‐Asian body mass index (BMI) classifications are commonly used as a risk factor for high fasting blood glucose (FBG). We investigated the incidence and factors associated with high FBG among people living with HIV in the Asia‐Pacific region, using a World Health Organization BMI classification specific to Asian populations.Methods: This study included people living with HIV enrolled in a longitudinal cohort study from 2003 to 2019, receiving antiretroviral therapy (ART), and without prior tuberculosis. BMI at ART initiation was categorized using Asian BMI classifications: underweight (2), normal (18.5–22.9 kg/m2), overweight (23–24.9 kg/m2), and obese (≥25 kg/m2). High FBG was defined as a single post‐ART FBG measurement ≥126 mg/dL. Factors associated with high FBG were analyzed using Cox regression models stratified by site.Results: A total of 3939 people living with HIV (63% male) were included. In total, 50% had a BMI in the normal weight range, 23% were underweight, 13% were overweight, and 14% were obese. Median age at ART initiation was 34 years (interquartile range 29–41). Overall, 8% had a high FBG, with an incidence rate of 1.14 per 100 person‐years. Factors associated with an increased hazard of high FBG included being obese (≥25 kg/m2) compared with normal weight (hazard ratio [HR] = 1.79; 95% confidence interval [CI] 1.31–2.44; p < 0.001) and older age compared with those aged ≤30 years (31–40 years: HR = 1.47; 95% CI 1.08–2.01; 41–50 years: HR = 2.03; 95% CI 1.42–2.90; ≥51 years: HR = 3.19; 95% CI 2.17–4.69; p < 0.001).Conclusion: People living with HIV with BMI >25 kg/m2 were at increased risk of high FBG. This indicates that regular assessments should be performed in those with high BMI, irrespective of the classification used.


  • Viral hepatitis and the cascade of care among people living with HIV in the Asia‐Pacific

    by Dhanushi Rupasinghe, Jun Yong Choi, Nagalingeswaran Kumarasamy, Sanjay Pujari, Ly Penh Sun, Tuti Parwati Merati, Man Po Lee, Nguyen Van Kinh, Sasisopin Kiertiburanakul, Cuong Duy Do, et al.

    Background Although the prevalence and mortality of hepatitis is high in the Asia-Pacific region, few studies are available on the diagnosis, treatment, and cure rates for viral hepatitis among people living with HIV in this area. This study aims to report the cascade of care (CoC) for hepatitis B (HBV) and C (HCV) among people living with HIV receiving combined antiretroviral therapy (ART). Methods Patients enrolled in the TREAT Asia HIV Observational Database Low Intensity Transfer (TAHOD-LITE) cohort, on ART, and with follow-up data from 2010 to 2019 were included. Patients were determined as positive for HCV or HBV co-infection if they ever tested positive for HCV antibody (anti-HCV) or HBV surface antigen (HBsAg), respectively. Results In total, 39% (8612/22 340) of the adult HIV cohort had undergone HBsAg testing, with 8% (672/8612) testing positive. HBV CoC demonstrated that 71% (474/672) of those with HBsAg positive results initiated treatment, 67% (318/474) of those on treatment had HBV DNA testing to evaluate treatment progression, and 18% (58/318) of those tested reached viral suppression. Of the cohort, 37% (8231/22 340) had anti-HCV testing, of whom 10% (779/8231) tested positive. The HCV CoC showed that 68% (526/779) of those with positive anti-HCV tests had HCV RNA tests, of whom 51% (267/526) had detectable HCV RNA. Among those with detectable HCV RNA, 65% (174/267) initiated HCV treatment. Of the 40% (69/174) who initiated HCV treatment, 90% (62/69) reached sustained virological response. Conclusion Our findings identified less frequent testing in the healthcare system and limited access to treatment as gaps in the CoC for viral hepatitis. More routine HCV RNA and HBV DNA testing is required for patients with positive screening tests to identify those in need of treatment.


  • Weight changes, metabolic syndrome and all‐cause mortality among Asian adults living with HIV

    by Win Min Han, Matthew G. Law, Jun Yong Choi, Rossana Ditangco, Nagalingeswaran Kumarasamy, Romanee Chaiwarith, Penh Sun Ly, Suwimon Khusuwan, Tuti Parwati Merati, Cuong Duy Do, et al.

    Objectives: We investigated weight changes following antiretroviral therapy (ART) initiation, the development of metabolic syndrome (MetS) and its association with all‐cause mortality among Asian adults living with HIV.Methods: Participants enrolled in a regional Asian HIV‐infected cohort with weight and height measurements at ART initiation were eligible for inclusion in the analysis. Factors associated with weight changes and incident MetS (according to the International Diabetic Federation (IDF) definition) were analysed using linear mixed models and Cox regression, respectively. Competing‐risk regression models were used to investigate the association of MetS with all‐cause mortality.Results: Among 4931 people living with HIV (PLWH), 66% were male. At ART initiation, the median age was 34 [interquartile range (IQR) 29–41] years, and the median (IQR) weight and body mass index (BMI) were 55 (48–63) kg and 20.5 (18.4–22.9) kg/m2, respectively. At 1, 2 and 3 years of ART, overall mean (± standard deviation) weight gain was 2.2 (±5.3), 3.0 (±6.2) and 3.7 (±6.5) kg, respectively. Participants with baseline CD4 count ≤ 200 cells/µL [weight difference (diff) = 2.2 kg; 95% confidence interval (CI) 1.9–2.5 kg] and baseline HIV RNA ≥ 100 000 HIV‐1 RNA copies/mL (diff = 0.6 kg; 95% CI 0.2–1.0 kg), and those starting with integrase strand transfer inhibitor (INSTI)‐based ART (diff = 2.1 kg; 95% CI 0.7–3.5 kg vs. nonnucleoside reverse transcriptase inhibitors) had greater weight gain. After exclusion of those with abnormal baseline levels of MetS components, 295/3503 had incident MetS [1.18 (95% CI 1.05–1.32)/100 person‐years (PY)]. The mortality rate was 0.7 (95% CI 0.6–0.8)/100 PY. MetS was not significantly associated with all‐cause mortality in the adjusted model (P = 0.236).Conclusions: Weight gain after ART initiation was significantly higher among those initiating ART with lower CD4 count, higher HIV RNA and an INSTI‐based regimen after controlling for baseline BMI. Greater efforts to identify and manage MetS among PLWH are needed.


  • Short Communication: Coronavirus Disease 19 Among People Living with HIV in Western India: An Observational Cohort Study

    by Sanjay Pujari, Sunil Gaikwad, Abhishek Chitalikar, Digamber Dabhade, Kedar Joshi, Vivek Bele

    A retrospective cohort study was conducted to assess clinical characteristics and outcomes of COVID-19 amongst People Living with HIV (PLHIV) in Western India. Out of 86 PLHIV with COVID-19 illness, 19.7% had severe/critical illness and 6 (6.9%) individuals died. Median (IQR) age was 51 (47-56) years and 77.6% were male. Eighty-five PLHIV were on antiretroviral treatment with 98% having a Viral load < 200 copies/ml. Hypertension (38.3%) and Diabetes mellitus (17.4%) were commonest co-morbidities. Fifty-eight percent PLHIV were hospitalized while 6.9% individuals needed Intensive care. Presence of medical co-morbidity was significantly associated with severe/critical COVID-19, while Hypertension was significantly associated with mortality. Recovery from COVID-19 was documented in 93% PLHIV. In conclusion, PLHIV in Western India have similar COVID-19 clinical outcomes as compared to that reported historically amongst general population. Presence of medical co-morbidities rather than HIV related disease characteristics are associated with severe COVID-19 illness.


  • Open Access

    Long‐coronavirus disease among people living with HIV in western India: An observational study

    by Sanjay Pujari, Sunil Gaikwad, Abhishek Chitalikar, Digamber Dabhade, Kedar Joshi, Vivek Bele

    Background: Long‐COVID is emerging as a significant problem among individuals who recovered from COVID‐19. Scant information is available on the prevalence, characteristics, and risk factors for long‐COVID among people living with HIV (PLHIV).Setting: A tertiary level, private, HIV clinic in western India.Methods: A prospective, observational study was conducted to assess the prevalence of long‐COVID among PLHIV. Long‐COVID was defined as the presence of at least one symptom after 30 days of illness onset. A questionnaire for assessing general, cardiorespiratory, neuro‐psychiatric, and gastro‐intestinal symptoms was used to screen individuals with history of confirmed COVID‐19. Data on demographics, HIV‐related variables, comorbidities, and severity of COVID‐19 were abstracted from electronic medical records. Univariate and multivariate logistic regression were used to identify risk factors for long‐COVID.Results: Ninety‐four PLHIV were screened for long‐COVID. Median (interquartile range [IQR]) age was 51 (47–56) years and 73.4% were males. The majority (76.6%) had a history of asymptomatic–mild COVID‐19 illness. The prevalence of long‐COVID was 43.6% (95% confidence interval [CI], 33.4–54.2). Moderate–severe COVID‐19 illness was significantly associated with long‐COVID (adjusted odds ratio, 4.7; 95% CI, 1.4–17.9; p = .016). Among individuals with long‐COVID, cough (22.3%) and fatigue (19.1%) were the commonest symptoms. The median (IQR) duration for resolution of symptoms was 15 (7–30) days. Ten individuals (10.6%) had persistent symptoms at a median of 109 days since the onset of COVID‐19.Conclusion: Long‐COVID is common among PLHIV with moderate–severe acute COVID‐19 illness. There is a need for integration of long‐COVID diagnosis and care services within antiretroviral therapy clinics for PLHIV with COVID‐19.


  • Pulmonary tuberculosis masquerading as coronavirus disease 2019 in an HIV-infected individual with advanced immune suppression

    by Sanjay Pujari, Piyush Gugale, Darshan Shah, Divya Patel, Sunil Gaikwad, Clyde Desouza, Ashish Atre

    An abstract is unavailable. This article is available as a PDF only.